Three technologies that could change the world

The Financial Times has consulted the experts in drug discovery and settled on three new technologies that promise to transform patient care in years to come. Most FierceBiotech readers are already familiar with RNAi, where a number of companies are competing to advance new therapies. GWAS is second on the list; individual genetic variations that highlight a person's risk of disease. Finally the FT lists IPSCs, the pluripotent stem cells that act like embryonic stem cells. Big challenges have yet to be met in the field, but the experts say the long-term potential here is amazing.

- read the article in the Financial Times

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.